Moreover, in TNBC and HER2-positive breast cancer cases where a pCR is not achieved with neoadjuvant therapy, escalation of adjuvant therapy can be offered to improve survival rates (capecitabine, TDM-1, olaparib, respectively) [40–42]. The gene discussed is ERBB2; the disease is breast cancer.